Robert Israel, MD

Professor of Obstetrics & Gynecology

Image of Robert Israel, MD
Is this your profile? Click to edit

Overview

Robert Israel, M.D., graduated with a BA in English and Anthropology from Harvard College, an MD from the University of Pennsylvania School of Medicine, and a residency in Obstetrics and Gynecology at The Johns Hopkins Hospital. He completed a post-residency, two-year obligation to the US Navy in the Department of Obstetrics and Gynecology at Balboa Naval Hospital in San Diego, California, where he established the first Infertility Clinic. He joined the new, full-time Department of Obstetrics and Gynecology at the University of Southern California (USC) School of Medicine in late 1969, and has remained a faculty member at that institution ever since, achieving professorial level. He has been a member of the department’s Executive Committee, since its inception in 1970. For over 25 years, he was the director of the department’s required medical student rotation. He chaired the division of gynecology at two different times for over 10 years. From 2005 -2007, he was the first director of development for the department. During that time period, he initiated two endowed department chairs and helped convert the department’s former resident organization into a significant alumni association. Presently, he is the chair of quality improvement for the department and director of the women’s health clinics. Nationally, he belongs to the Pacific Coast Reproductive Society and was its President in 1980, the American Society of Reproductive Medicine, the American College of Obstetricians and Gynecologists, and the Pacific Coast Obstetrical and Gynecological Society, having been its President in 2002 and, presently, the Chair of the Society’s Industry Liaison Committee. He has authored multiple, peer-reviewed publications, as well as book chapters. His medical interests include endometriosis, reproductive problems, myomata uteri, sterilization, intrauterine adhesions, and uterine congenital anomalies. Dr. Israel’s outside interests include the completion of ten marathons and classical theater, epitomized by his third appointment to the Board of Directors of A Noise Within, the classical repertory theater in the Los Angeles area.

Publications

  • First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis. J Emerg Med. 2022 Feb; 62(2):231-239.. View in PubMed
  • Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials. F1000Res. 2021; 10:891.. View in PubMed
  • Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies. J Pain Res. 2021; 14:2687-2697.. View in PubMed
  • Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series. Infect Dis Ther. 2021 Dec; 10(4):2791-2804.. View in PubMed
  • The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies. Support Care Cancer. 2021 Sep; 29(9):5209-5218.. View in PubMed
  • Malignancy Rates in Brodalumab Clinical Studies for Psoriasis. Am J Clin Dermatol. 2020 Jun; 21(3):421-430.. View in PubMed
  • Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancer. Pain Manag. 2020 Mar; 10(2):73-84.. View in PubMed
  • Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. Am J Clin Dermatol. 2019 Dec; 20(6):863-871.. View in PubMed
  • Immunogenicity and skin clearance recapture in clinical studies of brodalumab. J Am Acad Dermatol. 2020 Feb; 82(2):344-351.. View in PubMed
  • Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. Br J Dermatol. 2019 02; 180(2):306-314.. View in PubMed